Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer

被引：10
|
作者：
Kaisary, AV [1 ]
机构：
[1] Royal Free Hosp, Dept Urol, London NW3 2QG, England
来源：
PROSTATE CANCER AND PROSTATIC DISEASES | 2005年 / 8卷 / 02期
关键词：
prostate cancer; hormonal therapy; castration; luteinising hormone-releasing hormone agonist; nonsteroidal antiandrogen;
D O I：
10.1038/sj.pcan.4500800
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This article evaluates the use of early hormonal therapy in patients with localised or locally advanced prostate cancer. In patients receiving radiotherapy, an overall survival benefit is proven for adjuvant goserelin ('Zoladex') in locally advanced disease. Adjuvant to radical prostatectomy, castration ( goserelin or orchiectomy) has demonstrated an overall survival benefit in patients with lymph node metastases. Survival advantages have not yet been proven with nonsteroidal antiandrogens, but immediate or adjuvant bicalutamide ('Casodex') improves objective progression-free survival in patients with locally advanced disease, with certain quality-of-life advantages over castration.
引用
收藏
页码：140 / 151
页数：12
相关论文
共 50 条
  • [31] How should we treat patients with locally advanced prostate cancer?
    Mason, M
    EUROPEAN UROLOGY SUPPLEMENTS, 2003, 2 (09) : 14 - 22
  • [32] Advanced prostate cancer patients' ways of coping with the hormonal therapy's effect on body, sexuality, and spousal ties
    Navon, L
    Morag, A
    QUALITATIVE HEALTH RESEARCH, 2003, 13 (10) : 1378 - 1392
  • [33] Evaluation of therapeutic potential of heavy ion therapy for patients with locally advanced prostate cancer
    Nikoghosyan, A
    Schulz-Ertner, D
    Didinger, B
    Jäkel, O
    Zuna, I
    Höss, A
    Wannenmacher, M
    Debus, J
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (01): : 89 - 97
  • [34] Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis
    Neymark, N
    Adriaenssen, I
    Gorlia, T
    Caleo, S
    Bolla, M
    Brochon, D
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (14) : 1768 - 1774
  • [35] Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments
    Payne, H.
    Mason, M.
    BRITISH JOURNAL OF CANCER, 2011, 105 (11) : 1628 - 1634
  • [36] Hormonal therapy and chemotherapy in patients with hormone-sensitive prostate cancer
    Gafanov, R. A.
    ONKOUROLOGIYA, 2016, 12 (01): : 63 - 68
  • [37] Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments
    H Payne
    M Mason
    British Journal of Cancer, 2011, 105 : 1628 - 1634
  • [38] Locally advanced prostate cancer
    Klein E.A.
    Kupelian P.A.
    Dreicer R.
    Peereboom D.
    Zippe C.
    Current Treatment Options in Oncology, 2001, 2 (5) : 403 - 411
  • [39] Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy in Japanese patients with locally advanced prostate cancer
    Masato Sakamoto
    Takashi Mizowaki
    Michihide Mitsumori
    Kenji Takayama
    Keisuke Sasai
    Yoshiki Norihisa
    Toshiyuki Kamoto
    Eijiro Nakamura
    Osamu Ogawa
    Masahiro Hiraoka
    International Journal of Clinical Oncology, 2010, 15 : 571 - 577
  • [40] Optimal treatment of locally advanced prostate cancer
    Manfred P. Wirth
    Oliver W. Hakenberg
    Michael Froehner
    World Journal of Urology, 2007, 25 : 169 - 176
12345